Cetuximab, is a chimeric murine/human IgG1 monoclonal antibody (mAb) against EGFR, and is the Food and Drug Administration (FDA) approved targeted agent for the treatment of HNSCC. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.